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Abstract 
Colorectal or bowel cancer is one of the major causes of cancer worldwide. Research has shown that 15 to 20% 
colorectal cancer patients are also diagnosed with synchronous liver metastases (LM) at presentation and about 
one third eventually develop liver lesions.   Management of cases with colorectal cancer comorbid with liver 
metastases is more complex. This highlights the need for suggesting the need for effective treatment while 
optimizing timing during surgical and medical treatment of primary plus metastatic disease. Such patients cases 
are likely to present with severe cancer biology and thereby less likely to be long-term survivors. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Colorectal or bowel cancer is one of the major 
cause of cancer worldwide. Research has shown that 
15 to 20 % colorectal cancer patients are also 
diagnosed with synchronous liver metastases (LM) at 
presentation and about one third eventually develop 
liver lesions [1], [2]. Management of cases with 
colorectal cancer comorbid with liver metastases is 
more complex [3], [4]. This highlights the need for 
suggesting the need for effective treatment while 
optimizing timing during surgical and medical 
treatment of primary plus metastatic disease. 
According to Fong, Fortner, Sun, Brennan, and 
Blumgart, 1999 [5], such patients cases are likely to 
present with severe cancer biology and thereby less 
likely to be long-term survivors. 
The question as whether primary lesion 
surgery should precede metastases resection is still 
debatable. Logically, the management of these 
patients can be categorized into two groups. The first 
case is where the patients have hepatic disease 
synchronized with extrahepatic metastatic condition. 
These patients are treated with systemic 
chemotherapy as provided in the current treatment 
guidelines for patients with advanced multisite 
metastatic colorectal cancer disease [3], [6]. The 
second case is where patients have liver-limited 
synchronous metastatic disease which occurs 
frequently but yet a rising complex clinical 
management issue [7]. 
Conventionally, treatment of colorectal 
synchronous liver metastasis patients comprised 
colorectal primary tumour resection and then adjuvant 
chemotherapy in combination with liver resection [7], 
[8], [9]. However, Mentha, Majno, Andres, Rubbia-
Brandt, Morel, and Roth, 2006 [10], challenged this 
view by advocating for advanced synchronous liver 
metastases resection before the primary. 
For patients with synchronous metastases, 
major advancements in liver surgery have led to two 
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alternative options. The first involves synchronous 
liver metastases and colorectal primary resection 
synchronously [7], [9] which aims to remove 
macroscopic tumour burden through a single 
operation. However, this approach may lead to 
considerable complex morbidity with side effects on 
progression-free survival [11]. The second option 
starts with liver metastatic disease resection (i.e. 
reverse or liver-first approach) [10], [12]. This 
approach is commonly indicated for colorectal 
synchronous liver metastasis patients where rectal 
primary preoperative long-course chemoradiotherapy 
before surgical resection is likely to create a ‘window’ 
for liver resection [13], [14]. From oncological 
perspective, it is also arguable that the liver-first 
strategy is advantageous since it addresses the 
hepatic metastatic issue before it progresses into the 
liver which makes it unresectable  [15]. The focus of 
this study is to determine the order to be followed 
while treating patients with synchronous liver 
metastases and colon rectal cancer (liver first, colon 
first or syncrhonus surgery). 
 
 
Methods 
 
This study used a systematic review method 
to collect data from previous peer review papers. The 
researcher conducted a search of the relevant articles 
from various databases, namely PubMed and 
SCOPUS sciencedirect as well as EMBASE plus NHS 
Knowledge Network. All the collected articles were 
then subjected to assessment criteria for relevance 
and only seven articles met this criteria for literature 
review.  
 
 
Results and Discussion 
 
A systematic review by Guraya, 2013 [16] 
found that a number of factors limit most patients from 
undergoing resection at initial stages. These are size, 
anatomic location, and extent of disease to insufficient 
remnant liver volume as well as comorbidities. 
However, surgery currently provides the best chance 
for curing colorectal liver metastases patients. The 
implication is that other treatment modalities must be 
explored to control or downsize hepatic lesions prior 
to surgical treatment. Currently, most patients are 
treated with systemic plus regional chemotherapy to 
complement the surgical intervention. 
An expert opinion by Adam, 2007 [17], 
suggested that synchronous liver metastases 
management is changing with time. In his view, 
treatment of resectable lesions is open for either 
approach unlike irresectable lesions in which 
treatment starts with systemic chemotherapy. 
However, there is no evidence to support this 
approach as the first choice of treatment. The 
implication is that future research should explore on 
this issue using controlled trials. 
In a study by Per Pfeiffer, Thomas and 
Robert, 2018 [18] it was reported that there is no clear 
optimal sequence and individual usage despite that its 
use on individual basis. Additionally, the authors 
recommended multidisciplinary approach along with 
decision making for patients with rectal cancer (RC) 
and synchronous metastases. In the case of a 
multidisciplinary approach, treatment aim is first 
defined followed by regular follow up, re-evaluation 
and re-discussion after every 2 months. The authors 
recommended treatment initiation starting with the 
most effective systemic chemotherapy (i.e. triplet 
chemotherapy along with targeted therapy in view of 
RAS status) in combination multidisciplinary team 
(MDT) re-evaluation every 2 months. Moreover, they 
recommended that liver surgery should be initiated 
once colorectal liver metastases (CRLM) becomes 
resectable followed by systemic treatment prior to 
and/or after primary resection for a minimum of 6 
months. Furthermore, SC-RT may be combined with 
systemic chemotherapy at any point with or without 
minimal delay. 
René, Aimery, Joan, Norihiro, Francis, 
Evelyne et al., 2015 [19] recommended treatment of 
synchronous CRLM starting with abdominal high-dose 
contrast-enhanced computed tomography (CT) to 
establish the possibility of resection. In their views, 
asymptomatic CRC along with resectable 
synchronous CRCLM should be treated with 
chemotherapy with radiotherapy or chemotherapy 
alone then either one-stage surgery if hepatic disease 
is limited and easy-to-resect primary tumours or by 
use staged surgery for other patients. In patients with 
asymptomatic CRC along with non-resectable 
synchronous CRCLM, optimal chemotherapy is 
performed to make LM resectable and then hepatic 
surgery and primary tumour resection. The third 
option is applicable to patients with symptomatic CRC 
along with resectable synchronous CRCLM. In this 
case, primary tumour resection of perforated or 
occlusive tumours is done unlike the bleeding tumours 
which may cause anaemia and then chemotherapy in 
combination with LM surgery. Where patients have 
symptomatic CRC with non-resectable synchronous 
CRCLM, primary tumour resection for perforated or 
occlusive tumours should first be performed, then 
chemotherapy and finally LM surgery in case tumour 
shrinkage occurs. Patients with tumours with bleeding 
that cause anaemia should be treated with induction 
chemotherapy to downsize both primary tumour plus 
LM before operating sites with more significant tumour 
load such as the liver. 
Christian, Valentinus, Erik, Sam, Jan, Ingvar, 
& Gert, 2017 [20], presented 109 patients with un-
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resected colorectal cancer 9CRC) along with 
synchronous liver metastases to a MDT conference. 
Seventy-five patients were indicated for liver-first and 
the remaining 34 for classical strategy. The findings 
showed that 35% patients failed to complete the liver-
first treatment versus 10 patients from the classical 
strategy (P = 0.664). The failure rate was attributable 
to the most frequently disease progression. There 
were 91 patients who received the primary tumor 
resection prior to the liver metastasesOf these, 67 
were non-referrals and 24 after MDT allocation. 
Median survival following diagnosis in the primary 
tumour resection was 60 (48 to 73) months versus 46 
(31 to 60) months in the liver-first treatment group (n = 
49), (P = 0.310). The study concluded that a 
maximum of 35% colorectal cancer with synchronous 
liver metastases patients fail to complete the 
necessary liver plus bowel resections, regardless of 
the treatment strategy. 
 
 
Conclusion and Recommendations 
 
In general, this review found that the 
treatment order for patients with colorectal 
synchronous liver metastasis patients. The general 
observation is that patients with colorectal liver 
metastases should be treated with the most effective 
systemic chemotherapy in combination 
multidisciplinary team (MDT) re-evaluation every 2 
months. However, liver surgery should be performed 
once colorectal liver metastases (CRLM) becomes 
resectable followed by systemic treatment prior to 
and/or after primary resection for at least 6 months. 
However, this study recommends the need for future 
research to ascertain the best treatment options 
based on patient needs. 
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